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Laboratory preparedness with quality-assured diag-
nostic assays is essential for controlling the current 
coronavirus disease (COVID-19) outbreak. We con-
ducted an external quality assessment study with 
inactivated severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2) samples to support clinical labo-
ratories with a proficiency testing option for molecular 
assays. To analyse SARS-CoV-2 testing performance, 
we used an online questionnaire developed for the 
European Union project RECOVER to assess molecular 
testing capacities in clinical diagnostic laboratories.
Extensive laboratory testing is a prerequisite in con-
taining and mitigating the impact of the ongoing cor-
onavirus disease (COVID-19) pandemic while neither 
vaccine nor treatment are available [1]. Access to reli-
able diagnostic assays and adequate testing capac-
ity for the causing severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) is essential for prepared-
ness and response strategies worldwide [2]. Molecular 
methods such as RT-PCR are fundamental to early 
SARS-CoV-2 detection in suspected cases. Many in-
house and commercial assays have been developed 
rapidly [3,4]. However, the quality and diagnostic 
performance of these tests have not been adequately 
validated; the World Health Organization (WHO) has 
therefore encouraged laboratories to participate in 
external quality assessment (EQA) schemes for this 
novel virus [5]. Here, we present the results of a first 
EQA on molecular detection of SARS-CoV-2 introduced 
by Quality Control for Molecular Diagnostics (QCMD, 
Glasgow, Scotland), an independent International EQA 
organisation. We also present data from a survey by 
the European Union (EU) project RECOVER, a COVID-
19-related project originating from the EU-initiative 
Platform for European Preparedness Against (Re-)
emerging Epidemics (PREPARE), assessing the molecu-
lar testing capacity and throughput of clinical laborato-
ries in 36 countries.
Coronavirus outbreak preparedness EQA 
pilot study
Between 6 April and 20 May 2020, each participating 
laboratory received a blinded panel of eight samples, 
with five samples containing serial 10-fold dilutions 
(2.30–5.30 dPCR log10 RNA copies/mL, one duplicated) 
of non-infectious SARS-CoV-2-positive supernatant 
obtained from Vero cell culture, two samples with 
cell culture-derived common human coronavirus 
(HCoV-NL63, HCoV-OC43) and one negative control 
with transport medium only. Supernatants were clari-
fied by centrifugation at 300 × G for 10 min. In case of 
SARS-CoV-2, the material was heated (65 °C, 4 h) and 
gamma-irradiated (30 kGy) for inactivation. The 1.0-mL 
samples were pretested using the E gene assay (modi-
fied from [6]), and quantified by droplet digital PCR 
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(Bio-Rad, Hercules, United States (US)). The EQA pan-
els were shipped on dry ice. Participants were asked to 
treat and test the material like clinical samples using 
their routine molecular assay workflows and to report 
their results together with workflow details through 
a dedicated online reporting system. Laboratories 
submitted one dataset per applied workflow with 
extraction and amplification method used to test the 
provided samples.
In this first EQA round, 365 of 406 registered laborato-
ries from 36 countries (25 European, nine Australian-
Asian and two North American) submitted a total of 
521 datasets with qualitative results. All participants 
received a rapid report after submission of their 
results, followed by an EQA report with individual per-
formance and peer group assessment on completion of 
the study. The panel composition and overall perfor-
mance per sample are shown in Table 1.
Detecting all SARS-CoV-2-positive samples and the 
negative sample correctly was defined as an accept-
able level of proficiency. All core samples were 
correctly reported by 86.3% (315/365) of participating 
laboratories and in 83.1% (433/521) of datasets. When 
including the results reported for the two educational 
specificity samples, the overall percentage of correct 
results was 84.7% (309/365) on a laboratory level and 
81.8% (426/521) for datasets. Incorrect results (includ-
ing false-positive or not determined as laboratories 
should be able to report clear results by molecular 
methods) were reported for the true negative sample 
CVOP20S-05 in 14 (2.7%) datasets (with three false-
positive and 11 not determined), for the SARS-CoV-2 
negative educational sample CVOP20S-02 in 16 (3.1%) 
datasets (five false-positive, 11 not determined), and 
for the other SARS-CoV-2 negative educational sam-
ple CVOP20S-04 in 15 (2.9%) datasets (three false-
positive, 12 not determined). At the laboratory level, 
10 laboratories showed specificity issues by reporting 
false-positive or indeterminate results for the negative 
control and/or the two educational specificity samples, 
while 41 laboratories did not detect one or both of the 
two low-concentration samples (CVOP20S-08 and -03). 
Three laboratories showed both sensitivity and speci-
ficity issues and another two did not reproduce the 
Table 1
Coronavirus disease (COVID-19) outbreak preparedness EQA pilot study, panel composition and overall performance per 
sample, April/May 2020 (n =521)









Reported Cq values 
 
(For information purposes only)
% Total datasets Median (range) Total datasets





CVOP20S-02 HCoV-NL63 4.64 EDUC 96.9 521 NA NA





CVOP20S-04 HCoV-OC43 4.03 EDUC 97.1 521 NA NA
CVOP20S-05 Negative NA CORE 97.3 521 NA NA















Cq: quantification cycle; CVOP: Coronavirus outbreak preparedness; dPCR: digital PCR; EQA: external quality assessment; HCoV: human 
coronavirus: NA: not applicable; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
a Content of the EQA samples: SARS-CoV-2 strain BetaCoV/Munich/ChVir984/2020 provided by the Charité-Universitätsmedizin Berlin Institute 
of Virology, Berlin, Germany; human coronaviruses HCoV-NL63 and HCoV-OC43 cultivated by the University Medical Center Groningen, 
Groningen, the Netherlands, and sample specifications selected based on past performance data from regular provided coronavirus EQA 
schemes; negative control sample contained transport medium only (which was used as sample matrix for the EQA samples).
b Values obtained using a dPCR assay (modified from [6]). Samples CVOP20S-07, -01, -03 and - 08 are in a calibrated dilution series. 
CVOP20S-06 is a duplicate sample of CVOP20S-01. The values provided are for reference only and have been established to support the 
consistency and traceability of the EQA materials as well as comparison of results across participating laboratories.
c EQA samples are defined as ‘CORE’ or ‘EDUC’ (educational). Core proficiency samples are reviewed by scientific experts, based on scientific 
information, clinical relevance, current literature and where appropriate, professional clinical guidelines. Participating laboratories were 
expected to report the core proficiency samples (here: all SARS-CoV-2-positive samples and the negative control) correctly within the EQA 
scheme. Samples CVOP20S-02 and CVOP20S-04 were included in the panel as educational specificity samples and were expected to be 
reported as SARS-CoV-2 negative. Participants were not expected to report on the identity of the common human coronaviruses HCoV-NL63 
or HCoV-OC43.
3www.eurosurveillance.org
results for the duplicated samples (CVOP20S-01 and 
-06).
Many participants provided quantification cycle (Cq) 
values in this EQA scheme. An overall median and 
range of the Cq values reported is shown for each 
SARS-CoV-2 positive sample in Table 1. While the medi-
ans reflect the expected gradation according to the 
virus concentration in the 10-fold sample dilutions, we 
observed considerable spread in Cq values with regard 
to the underlying target genes. This reflects differences 
in assay methods and the current lack of standardisa-
tion between assays. However, the overall percentage 
of correctly reported qualitative results was 98.3% for 
the E gene (reported in 197 datasets), 93.3% for the 
N gene (91 datasets), 96.3% for the ORF1ab gene (88 
datasets), 95.6% for the RdRP gene (83 datasets) and 
93.9% for the S gene (47 datasets) when used as the 
respective main molecular target (15 datasets did not 
state the target gene).
Logistic regression statistics, performed in SAS version 
9.4 (SAS Institute Inc., Cary, US), was used to assess 
whether common technical factors, such as the extrac-
tion and amplification groups (by methods) listed 
in  Table 2, influenced participant performance. Both 
extraction and amplification method were statistically 
significantly associated with correct classification of all 
samples (p < 0.001 for both). While the overall percent-
age of correct results was above 90% for each analysed 
group, certain groups showed statistically significant 
differences compared with the corresponding reference 
level, namely ‘any other extraction method’ or ‘any 
real-time in-house PCR’. As an example, for one fully 
automated approach (Certest VIASURE SARS-CoV-2 
S gene real-time PCR kit (Certest, Zaragoza, Spain) 
used with the BD MAX system (Becton, Dickinson and 
Company, Franklin Lakes, US)) combining RNA extrac-
tion and subsequent real-time PCR (with only 90.3% 
and 90.8% overall correct results, respectively), all 14 
false-negative results reported by 13 laboratories could 
be clearly linked to sensitivity issues with the two low-
concentration samples in the panel. However, some of 
Table 2
Factors influencing the performance of Coronavirus disease (COVID-19) outbreak preparedness EQA participants, logistic 
regressions on combined responses reported for all samples in the panel, April/May 2020 (n = 4,168)
Possible technical influence factors (grouped by 
methods)
Total responses per 
group
Percentage correct 




Extraction method (overall) 4,168 96.3 4,012  < 0.001*
Any other method (incl. seven in-house) 1,152 94.6 1,090 Reference level
Abbott m2000sp 168 99.4 167 0.026* 9.50 1.31–68.97
BD MAX ExK TNA-3 144 90.3 130 0.040* 0.53 0.29–0.97
Roche Cobas Omni 304 99.3 302 0.003* 8.59 2.09–35.32
PSS MagDEA Dx 72 100 72 0.974 NA NA
Roche MagNA Pure 96 DNA and Viral 336 96.7 325 0.119 1.68 0.88–3.23
Promega Maxwell RSC (Viral/Blood) 176 95.5 168 0.644 1.19 0.56–2.54
BioMérieux NucliSENS easyMAG 544 98.4 535 < 0.001* 3.38 1.67–6.86
Qiagen QIAamp Viral RNA Mini Kit 184 98.9 182 0.023* 5.18 1.26–21.35
Qiagen QIAsymphony DSP Virus 144 97.2 140 0.189 1.99 0.71–5.56
Seegene STARMag Universal Cart. 360 98.1 353 0.009* 2.87 1.30–6.32
Cepheid Xpert Xpress SARS-CoV-2 376 94.4 355 0.880 0.96 0.58–1.60
Not specified 208 92.8 193 0.295 0.73 0.41–1.31
Amplification method (overall) 4,168 96.3 4,012  < 0.001*
Any real-time in-house PCR 952 96.7 921 Reference level
Abbott RealTime SARS-CoV-2 136 99.3 135 0.138 4.54 0.62–33.53
Altona RealStar SARS-CoV-2 RT-PCR 224 99.1 222 0.072 3.74 0.89–15.73
Cepheid Xpert Xpress SARS-CoV-2 408 94.9 387 0.098 0.62 0.35–1.09
Certest VIASURE SARS-CoV-2 136 91.9 125 0.008* 0.38 0.19–0.78
Certest VIASURE SARS-CoV-2 S gene 152 90.8 138 < 0.001* 0.33 0.17–0.64
Elitech GeneFinder COVID-19 Plus 200 95.0 190 0.230 0.64 0.31–1.33
Roche cobas SARSCoV2 296 99.3 294 0.029* 4.94 1.18–20.77
Seegene Allplex 2019-nCoV 552 98.9 546 0.013* 3.06 1.27–7.39
TIB MOLBIOL LightMix Modular 216 98.6 213 0.153 2.39 0.72–7.89
Any other commercial test kit 896 93.9 841 0.004* 0.52 0.33–0.81
NA: not applicable.
* Statistically significant; p ≤ 0.05 (for details see text).
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the observed differences for the groups listed in Table 
2 could also be due to improper handling of the assays 
and/or the samples, since laboratories using the 
same assays showed large variations in their reported 
qualitative results (e.g. because of differences in the 
parameters used for indeterminate results). 
Discussion
The data from this EQA study provide a comparison of 
available molecular assays for SARS-CoV-2 detection. 
About 23% of the used assays were in-house assays 
which performed at least as well as commercial ones 
or even better. The overall qualitative performance of 
the participating laboratories was at an acceptable 
level and showed similar rates of successful partici-
pation as compared with the molecular EQA for SARS 
(provided by WHO/European Network for Diagnostics 
of “Imported” Viral Diseases (ENIVD)) during the out-
break in 2002 and 2003, with similar requirements and 
rapid developments for diagnostics, where 51 of 58 
laboratories from 38 countries achieved an acceptable 
level of proficiency [7]. Our EQA pilot study presented 
here revealed that analytical sensitivity and specificity 
remained variable.
Procedures should be reviewed where false-positive or 
indeterminate results have been reported which may 
lead to misdiagnosis and affect clinical decision mak-
ing. As highly sensitive methods are required for early 
COVID-19 diagnostic screening, two low-concentration 
samples were included in the EQA panel close to the 
detection limit of published or commercial assays 
[3,4,8-10]. Laboratories that were unable to detect 
low-concentration samples, or whose methods showed 
Cq values greatly different from the provided medi-
ans, should strive to improve the sensitivity of their 
molecular assays to prevent false-negative results in 
respiratory samples with low viral concentrations from 
SARS-CoV-2-infected patients, e.g. during the early 
phase of infection.
Survey on preparedness of diagnostic 
laboratories for SARS-CoV-2 detection
In parallel with the EQA study, laboratories were sur-
veyed to assess their challenges in implementing and 
executing molecular testing capacity and throughput 
for SARS-CoV-2 detection, also in April and May 2020. 
Of the 365 laboratories that participated in our EQA 
pilot study, five were excluded from the survey as they 
were engaged in assay development rather than in rou-
tine SARS-CoV-2 detection.
Almost 80% of the participating laboratories (n = 360) 
are capable of generating a SARS-CoV-2 PCR result 
within 24 h after receiving the sample (Supplementary 
Figure S1). This turnaround time is comparable to the 
results of a smaller survey (n = 87 laboratories) per-
formed earlier in the COVID-19 pandemic [11]. The daily 
test capacity, however, was much higher, with 48% of 
the laboratories capable of analysing more than 250 
samples per day, while only 41% in the previous survey 
could handle more than 50 samples [11]. More than 70% 
of the laboratories indicated that collaboration with 
reference laboratories and (inter)national public health 
institutes has helped in establishing SARS-CoV-2 test-
ing capability and capacity. However, challenges in 
implementation and execution of the testing remain, 
with lack of personnel/time and equipment being 
the predominant ones (Supplementary Figure S2). 
Compared with the earlier survey, challenges did shift 
over time, with lack of funding, an authorised mandate 
or unavailability of positive control material and/or a 
specificity panel becoming less important barriers.
Conclusions
Molecular testing capacity and throughput on clinical 
diagnostic level have been rapidly implemented and 
should be supported by proficiency testing panels. 
EQA schemes, such as the one presented here, are a 
good opportunity for laboratories to assess the per-
formance of their assays against international peer 
groups in line with agreed clinical practice, based 
on well-characterised samples, to identify any weak-
nesses with their procedures or methods. Laboratories 
should be aware of the limitations of their assays and 
perform their own validation and verification in line 
with ISO 15189 or equivalent requirements. Also, EQA 
data can provide valuable information for post-market 
surveillance of commercial assays, which is of particu-
lar importance in outbreak situations where data about 
the relative performance of methods are still limited 
and further clinical evaluations are ongoing. This way, 
the quality of COVID-19 diagnostic testing can be con-
tinuously ensured. Regional-specific EQA studies can 
also be done, but require a different approach in order 
to ensure comparability. For 2020, two further EQA 
programmes are planned by QCMD: a follow-up SARS-
CoV-2 EQA study and a respiratory EQA scheme com-
prising SARS-CoV-2 and other respiratory pathogens 
[12].
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